Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Peripheral Blood CD4/CD8 Ratio Predicts Out-of-Specification Products in Lisocabtagene Maraleucel Manufacturing.

Cancer reports (Hoboken, N.J.)·2025

Same author

Correction: Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others.

International journal of hematology·2025

Same author

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: part 4-trauma, burn, obstetrics, acute pancreatitis/liver failure, and others.

International journal of hematology·2025

Same author

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 3: solid cancers and vascular abnormalities.

International journal of hematology·2025

Same author

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 1: sepsis.

International journal of hematology·2024

Same author

Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024. Part 2: hematologic malignancy.

International journal of hematology·2024

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

[Mixing test for prolonged clotting time: clinical availability and problems].

Mitsuhiro Uchiba¹, Yukio Ando

¹Department of Blood Transfusion and Cell Therapy, Kumamoto University Hospital, Kumamoto 860-8556, Japan. mituhiro-uchiba@fc.kuh.kumamoto-u.ac.jp

Rinsho Byori. the Japanese Journal of Clinical Pathology

|November 26, 2009

Summary

This summary is machine-generated.

Prothrombin time (PT) and activated partial thromboplastin time (APTT) are essential for diagnosing bleeding disorders. Mixing tests help differentiate causes of prolonged clotting times, including inhibitors and heparin contamination.

More Related Videos

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Related Experiment Videos

Last Updated: Jun 18, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Area of Science:

Hematology
Clinical Pathology

Context:

Prothrombin time (PT) and activated partial thromboplastin time (APTT) are fundamental coagulation assays.
Prolonged clotting times can indicate bleeding disorders, inhibitors, or artifactitious causes like heparin contamination.

Purpose:

To summarize the causes of prolonged clotting times.
To highlight the utility of mixing tests in differentiating these abnormalities.

Summary:

This review discusses the differential diagnosis of prolonged clotting times.
It covers causes such as congenital hemophilia, lupus anticoagulant, factor inhibitors, and heparin contamination.
The diagnostic value of mixing tests is emphasized for accurate patient management.

Impact:

Provides a concise overview for clinicians and laboratory professionals.
Aids in the accurate diagnosis and management of coagulation disorders.
Improves understanding of inhibitor-related bleeding conditions.